In ovarian cancer, benefit from seribantumab was restricted to the patients with low levels of HER2 (<126,000 receptors/cell), whereas in the NSCLC and hormone receptor-positive and HER2-negative breast cancer study all tumor biopsies obtained tested below these HER2 levels. Here, ERBB2 is linked to ovarian carcinoma.